Targeted delivery of YSA-functionalized and non-functionalized polymeric nanoparticles to injured pulmonary vasculature

References

• Pierrakos C, Karanikolas M, Scolletta S, et al. Acute respiratory distress syndrome: pathophysiology and therapeutic options. J Clin Med Res 2012; 4:7–16.
   PubMedGoogle Scholar
• Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334–1349.
   PubMed Web of Science ®Google Scholar
• Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 2016;315:788–800.
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Caironi P, Pelosi P, et al. What has computed tomography taught us about the acute respiratory distress syndrome? Am J Respir Crit Care Med. 2001;164:1701–1711.
   PubMed Web of Science ®Google Scholar
• Millar FR, Summers C, Griffiths MJ, et al. The pulmonary endothelium in acute respiratory distress syndrome: insights and therapeutic opportunities. Thorax 2016;71:462–473.
   PubMed Web of Science ®Google Scholar
• Coulthard MG, Morgan M, Woodruff TM, et al. Eph/Ephrin signaling in injury and inflammation. Am J Pathol. 2012;181:1493–1503.
   PubMed Web of Science ®Google Scholar
• Cheng N, Brantley DM, Liu H, et al. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 2002;1:2–11.
   PubMed Web of Science ®Google Scholar
• Fang BW, Ireton RC, Zhuang GL, et al. Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism. J Cell Sci. 2008;121:358–368.
   PubMed Web of Science ®Google Scholar
• Carpenter TC, Schroeder W, Stenmark KR, et al. Eph-A2 promotes permeability and inflammatory responses to bleomycin-induced lung injury. Am J Respir Cell Mol Biol. 2012;46:40–47.
   PubMed Web of Science ®Google Scholar
• Cercone MA, Schroeder W, Schomberg S, et al. EphA2 receptor mediates increased vascular permeability in lung injury due to viral infection and hypoxia. Am J Physiol Lung Cell Mol Physiol. 2009;297:L856–L863.
   PubMed Web of Science ®Google Scholar
• Hong JY, Shin MH, Chung KS, et al. EphA2 receptor signaling mediates inflammatory responses in lipopolysaccharide-induced lung injury. Tuberc Respir Dis. 2015;78:218–226.
   PubMed Web of Science ®Google Scholar
• Duxbury MS, Ito H, Zinner MJ, et al. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness. Biochem Biophys Res Commun. 2004;320:1096–1102.
   PubMed Web of Science ®Google Scholar
• Singh SR, Grossniklaus HE, Kang SJ, et al. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther. 2009;16:645–659.
   PubMed Web of Science ®Google Scholar
• Gobin AM, Moon JJ, West JL. EphrinA I-targeted nanoshells for photothermal ablation of prostate cancer cells. Int J Nanomedicine. 2008;3:351–358.
   PubMed Web of Science ®Google Scholar
• Koolpe M, Dail M, Pasquale EB. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem. 2002;277:46974–46979.
   PubMed Web of Science ®Google Scholar
• Scarberry KE, Dickerson EB, McDonald JF, et al. Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells. J Am Chem Soc. 2008;130:10258–10262.
   PubMed Web of Science ®Google Scholar
• Mitra S, Duggineni S, Koolpe M, et al. Structure-activity relationship analysis of peptides targeting the EphA2 receptor. Biochemistry. 2010;49:6687–6695.
   PubMed Web of Science ®Google Scholar
• Lee HY, Mohammed KA, Kaye F, et al. EphA2 targeted intratumoral therapy for non-small cell lung cancer using albumin mesospheres. Am J Transl Res. 2017;9:3293–3303.
   PubMed Web of Science ®Google Scholar
• Alkilany AM, Boulos SP, Lohse SE, et al. Homing peptide-conjugated gold nanorods: the effect of amino acid sequence display on nanorod uptake and cellular proliferation. Bioconjugate Chem. 2014;25:1162–1171.
   PubMed Web of Science ®Google Scholar
• Guo ZM, He B, Yuan L, et al. Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers. Int J Pharm. 2015;493:380–389.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang C, Fan L, et al. Brain delivery of NAP with PEG-PLGA nanoparticles modified with phage display peptides. Pharm Res. 2013;30:1813–1823.
   PubMed Web of Science ®Google Scholar
• Kompella UB. Nanotechnology and drug delivery. J Ocul Pharmacol Ther. 2013;29:89.
   PubMed Web of Science ®Google Scholar
• Kompella UB, Lee VH. Delivery systems for penetration enhancement of peptide and protein drugs: design considerations. Adv Drug Deliv Rev. 2001;46:211–245.
   PubMed Web of Science ®Google Scholar
• Sundaram S, Trivedi R, Durairaj C, et al. Targeted drug and gene delivery systems for lung cancer therapy. Clin Cancer Res. 2009;15:7299–7308.
   PubMed Web of Science ®Google Scholar
• Scheinman RI, Trivedi R, Vermillion S, et al. Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model. Nanomedicine (Lond). 2011;6:1669–1682.
   PubMed Web of Science ®Google Scholar
• Shelke NB, Kadam R, Tyagi P, et al. Intravitreal poly(L-lactide) microparticles sustain retinal and choroidal delivery of TG-0054, a hydrophilic drug intended for neovascular diseases. Drug Deliv Transl Res. 2011;1:76–90.
   PubMed Web of Science ®Google Scholar
• Koushik K, Kompella UB. Preparation of large porous deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process. Pharm Res. 2004;21:524–535.
   PubMed Web of Science ®Google Scholar
• Li J, Wang Y, Zhu Y, et al. Recent advances in delivery of drug-nucleic acid combinations for cancer treatment. J Control Release. 2013;172:589–600.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Neoh KG, Xu LQ, et al. Functionalized mesoporous silica nanoparticles with mucoadhesive and sustained drug release properties for potential bladder cancer therapy. Langmuir. 2014;30:6151–6161.
   PubMed Web of Science ®Google Scholar
• Almeida PV, Shahbazi MA, Makila E, et al. Amine-modified hyaluronic acid-functionalized porous silicon nanoparticles for targeting breast cancer tumors. Nanoscale. 2014;6:10377–10387.
   PubMed Web of Science ®Google Scholar
• Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161:505–522.
   PubMed Web of Science ®Google Scholar
• Semete B, Booysen L, Lemmer Y, et al. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomed Nanotechnol Biol Med. 2010;6:662–671.
   PubMed Web of Science ®Google Scholar
• Schleh C, Semmler-Behnke M, Lipka J, et al. Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration. Nanotoxicology. 2012;6:36–46.
   PubMed Web of Science ®Google Scholar
• Thasneem YM, Sajeesh S, Sharma CP. Effect of thiol functionalization on the hemo-compatibility of PLGA nanoparticles. J Biomed Mater Res. 2011;99A:607–617.
   Web of Science ®Google Scholar
• Wang JL, Liu YL, Li Y, et al. EphA2 targeted doxorubicin stealth liposomes as a therapy system for choroidal neovascularization in rats. Invest Ophthalmol Vis Sci. 2012;53:7348–7357.
   PubMed Web of Science ®Google Scholar
• Friedman AD, Claypool SE, Liu R. The smart targeting of nanoparticles. Curr Pharm Des. 2013;19:6315–6329.
   PubMed Web of Science ®Google Scholar
• Wang S, Noberini R, Stebbins JL, et al. Targeted delivery of paclitaxel to EphA2-expressing cancer cells. Clin Cancer Res. 2013;19:128–137.
   PubMed Web of Science ®Google Scholar
• Chan B, Sukhatme VP. Receptor tyrosine kinase EphA2 mediates thrombin-induced upregulation of ICAM-1 in endothelial cells in vitro. Thromb Res. 2009;123:745–752.
   PubMed Web of Science ®Google Scholar
• Costanzo M, Carton F, Marengo A, et al. Fluorescence and electron microscopy to visualize the intracellular fate of nanoparticles for drug delivery. Eur J Histochem. 2016;60:2640.
   PubMed Web of Science ®Google Scholar
• Kim JW, Rhee CK, Kim TJ, et al. Effect of pravastatin on bleomycin-induced acute lung injury and pulmonary fibrosis. Clin Exp Pharmacol Physiol. 2010;37:1055–1063.
   PubMed Web of Science ®Google Scholar
• Aono Y, Nishioka Y, Inayama M, et al. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Critical Care Med 2005;171:1279–1285.
   PubMed Web of Science ®Google Scholar
• Szapiel SV, Elson NA, Fulmer JD, et al. Bleomycin-induced interstitial pulmonary-disease in the nude, athymic mouse. Am Rev Respir Dis 1979;120:893–899.
   PubMed Web of Science ®Google Scholar
• Chandler DB, Hyde DM, Giri SN. Morphometric estimates of infiltrative cellular changes during the development of bleomycin-induced pulmonary fibrosis in hamsters. Am J Pathol 1983;112:170–177.
   PubMed Web of Science ®Google Scholar
• Smith RE, Strieter RM, Zhang K, et al. A role for C-C chemokines in fibrotic lung disease. J Leukoc Biol. 1995;57:782–787.
   PubMed Web of Science ®Google Scholar
• El-Khouly D, El-Bakly WM, Awad AS, et al. Thymoquinone blocks lung injury and fibrosis by attenuating bleomycin-induced oxidative stress and activation of nuclear factor Kappa-B in rats. Toxicology 2012;302:106–113.
   PubMed Web of Science ®Google Scholar
• Anselmo AC, Gupta V, Zern BJ, et al. Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. ACS Nano. 2013;7:11129–11137.
   PubMed Web of Science ®Google Scholar
• Blake LH, Staub NC. Pulmonary vascular transport in sheep. A mathematical model. Microvasc Res. 1976;12:197–220.
   PubMed Web of Science ®Google Scholar